RT Journal Article
SR Electronic
T1 ATL
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 1262
OP 1267
DO 10.1097/IGC.0000000000000183
VO 24
IS 7
A1 Shazia Bashir
A1 Gaofeng Jiang
A1 Ayesha Joshi
A1 Christopher Miller
A1 Cathleen Matrai
A1 Anna Yemelyanova
A1 Thomas A. Caputo
A1 Kevin M. Holcomb
A1 Lora Hedrick Ellenson
A1 Divya Gupta
YR 2014
UL http://ijgc.bmj.com/content/24/7/1262.abstract
AB Objectives Type II endometrial carcinomas—uterine carcinosarcomas or uterine malignant mesodermal mixed tumors (UMMMTs), clear cell carcinomas (UCCs), and uterine serous carcinomas (USCs)—are aggressive malignancies that present with advanced disease and have high mortality rates. PIK3CA mutations are commonly found in endometrial cancers. The objective of the study was to characterize molecular alterations in the PIK3CA gene in these tumors.Methods A total of 84 cases (20 UMMMTs, 18 UCCs, and 46 USCs) were selected from the surgical pathology files of Weill Cornell Medical College and Johns Hopkins Hospital. The diagnoses were confirmed by gynecologic pathologists (L.H.E. and A.Y.). DNA was extracted from paraffin-embedded tissue. Polymerase chain reaction was performed for mutational analysis. All the studies were performed in accordance with approved Institutional Review Board protocols.Results Mutations in the PIK3CA gene were identified in 3 (15%) of 20 UMMMT, 3 (16.7%) of 18 UCC, and 10 (21.7%) of 46 USC cases. We report novel mutations in PIK3CA in uterine carcinosarcoma.Conclusions A significant percentage of UMMMTs, UCCs, and USCs have mutations in PIK3CA. Further investigation is needed to develop targeted therapies for these aggressive uterine cancers.